All In Biotech

Drug Trial Radar · NCT01011205

Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation

A Multicenter, Three Arm, Randomized, Open Label Clinical Study to Compare Renal Function in Liver Transplant Recipients Receiving an Immunosuppressive Regimen of Advagraf (Immediately or Delayed Post-transplant) and MMF With or Without a Monoclonal Anti-IL2R Antibody (Basiliximab)

Last checked: Nov 19, 2026Latest source record: Nov 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 893 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

893

Actual

Start

Sep 30, 2009

Primary completion

Jan 4, 2013

Study completion Jan 4, 2013

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Nov 11, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Comparison of 3 dosing regimens of Advagraf to determine if there is a dosing regimen which may have the potential to cause fewer kidney problems.

Conditions

  • Liver Transplantation

Interventions

  • AdvagrafDrug

    Capsule

  • Mycophenolate MofetilDrug

    Solution for infusion

  • BasiliximabDrug

    IV infusion

  • CorticosteroidsDrug

    IV bolus

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Glomerular filtration rate (GFR) at 24 Weeks after transplantation estimated using the MDRD4 formulaTime frame: 24 weeks

Locations

72 sites in 23 countries. Site status is shown where the registry gives one.

  • 160

    Buenos Aires, Argentina

  • 001

    Innsbruck, Austria

  • 146

    Minsk, Belarus

  • 008

    Brussels, Belgium

  • 006

    Ghent, Belgium

  • 009

    Leuven, Belgium

  • 010

    Liège, Belgium

  • 163

    São Paulo, Brazil

  • 153

    Edmonton, Canada

  • 150

    Halifax, Canada

  • 151

    London, Canada

  • 152

    Montreal, Canada

  • 154

    Vancouver, Canada

  • 169

    Bogata, Colombia

  • 147

    Prague, Czechia

  • 026

    Helsinki, Finland

  • 041

    Besançon, France

  • 157

    Bordeaux, France

  • 043

    Caen, France

  • 031

    Créteil, France

  • 039

    Lyon, France

  • 045

    Marseille, France

  • 158

    Montpelier, France

  • 037

    Nice, France

  • 042

    Paris, France

  • 044

    Paris, France

  • 035

    Paris, France

  • 038

    Strasbourg, France

  • 033

    Toulouse, France

  • 034

    Villejuif, France

  • 056

    Berlin, Germany

  • 058

    Erlangen, Germany

  • 051

    Frankfurt, Germany

  • 055

    Göttingen, Germany

  • 057

    Hanover, Germany

  • 142

    Jena, Germany

  • 053

    Kiel, Germany

  • 054

    Leipzig, Germany

  • Site: 156

    Mainz, Germany

  • 052

    Münster, Germany

Showing 40 of 72 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.